Complement System

The complement system (or complement cascade) is an evolutionarily ancient proteolytic effector arm of immunology and host defense comprising more than 50 soluble plasma proteins, cell-surface receptors, and regulatory glycoproteins that circulate as inactive precursors (zymogens) and assemble rapidly on microbial surfaces to eliminate invading pathogens and damaged host cells. Synthesized predominantly by hepatocytes in the liver (with local production by tissue macrophages, monocytes, and epithelial cells), complement proteins account for roughly 5% to 10% of the total globulin fraction of human blood serum (with the central component C3 circulating at ~1.2–1.5 mg mL⁻¹). When triggered by pathogen-associated molecular patterns or antigen-bound antibodies, the cascade executes an amplifying series of site-specific serine protease cleavages that deliver three coordinated effector outcomes: (1) covalent opsonization of microbes for phagocytosis, (2) release of potent anaphylatoxin peptides that drive acute inflammation and leukocyte recruitment, and (3) assembly of the pore-forming Membrane Attack Complex (MAC, C5b–9) that directly lyses susceptible bacteria and enveloped virions.

The discovery of the complement system dates to the 1890s, when Hans Buchner and the Belgian immunologist Jules Bordet (awarded the 1919 Nobel Prize in Physiology or Medicine) demonstrated that fresh antiserum against Vibrio cholerae requires two distinct factors to lyse bacteria: a heat-stable sensitizing factor (specific antibody, which survives heating at 56 °C for 30 minutes) and a non-specific, heat-labile serum activity that is inactivated at 56 °C. Bordet termed this heat-labile lytic factor alexine, which Paul Ehrlich in 1899 renamed Komplement ("that which completes" the action of antibody). In 1954, Louis Pillemer discovered properdin and the antibody-independent alternative pathway, and in the late 1980s, Toshisuke Kawasaki and Jens Christian Jensenius characterized the lectin pathway, establishing that complement arose in early metazoans hundreds of millions of years before the evolution of adaptive immunoglobulins.

In nomenclature standardized by the World Health Organization, classical and terminal components are numbered C1 through C9 (note that in the historical order of discovery, C4 is cleaved before C2 and C3), whereas alternative pathway proteins are designated as Factors (Factor B, Factor D, Factor H, Factor I, and Properdin [Factor P]). Upon proteolytic cleavage of a zymogen, the smaller soluble peptide fragment that diffuses away is typically assigned the suffix "a" (e.g., C3a, C4a, C5a), while the larger fragment that remains bound to the microbial surface is assigned the suffix "b" (e.g., C3b, C4b, C5b; in modern immunology, the catalytic fragment of C2 is also denoted C2a or C2b depending on convention, with C4b2a representing the canonical classical C3 convertase).

---

All three initiation pathways of the complement cascade operate as molecular pattern-recognition sensors that converge on a single biochemical bottleneck: the assembly of a surface-bound C3 convertase enzyme complex that cleaves native C3 (a 185-kDa disulfide-linked α/β heterodimer) into the anaphylatoxin C3a (9 kDa) and the reactive opsonin C3b (176 kDa).

1. The Classical Pathway (C1qr₂s₂ → C4b2a)

The classical pathway is initiated when the C1 complex (~790 kDa, comprising one hexameric bouquet-shaped recognition protein C1q non-covalently associated with a Ca²⁺-dependent tetramer of two zymogen serine proteases, C1r₂C1s₂) binds to the Fc regions of antibodies complexed with antigen on a target surface. To activate C1r, at least two globular heads of C1q must bind simultaneously to C_H2/C_H3 Fc domains spaced ~30–40 nm apart:

• Pentameric or Hexameric IgM: Circulating free IgM adopts a planar conformation in which its C1q-binding sites are sterically hidden. Upon multivalent binding to a bacterial surface, IgM bends into a staple (crab-like) conformation that exposes multiple C1q-binding sites within a single molecule, making a single bound IgM molecule a potent activator of complement.
• Monomeric IgG (IgG3 > IgG1 > IgG2; IgG4 does not fix complement): Because each IgG monomer has only one Fc stem, at least two—and optimally six IgG molecules assembled via Fc–Fc interactions into a surface hexamer—must cluster in close proximity to engage C1q.

Mechanical strain transmitted through the collagen-like stalks of C1q triggers autocatalytic cleavage of C1r, which then cleaves and activates C1s. Active C1s sequentially cleaves two plasma substrates:

1. C1s cleaves C4 into soluble C4a and C4b, exposing an internal reactive thioester bond inside C4b that forms a covalent ester or amide linkage with hydroxyl (–OH) or amino (–NH₂) groups on the adjacent pathogen surface.
2. Surface-bound C4b binds C2 in a Mg²⁺-dependent manner; C1s then cleaves C2 to leave the catalytic subunit C2a attached to C4b, forming the classical C3 convertase (C4b2a).

2. The Lectin Pathway (MBL / Ficolins + MASPs → C4b2a)

Structurally homologous to the C1 complex, the lectin pathway is initiated without antibodies by soluble pattern-recognition collectins—principally mannose-binding lectin (MBL) and ficolins (H-, L-, and M-ficolin)—whose carbohydrate-recognition domains require Ca²⁺ to bind spaced arrays of terminal D-mannose, L-fucose, and N-acetyl-D-glucosamine (GlcNAc) characteristic of bacterial peptidoglycan, fungal mannans, and viral envelopes (while ignoring mammalian glycoproteins, whose glycans terminate in galactose and sialic acid). Bound MBL or ficolins activate associated serine proteases MASP-1 and MASP-2 (MBL-associated serine proteases, evolutionary homologs of C1r and C1s), which cleave C4 and C2 to assemble the exact same C4b2a C3 convertase used by the classical pathway.

3. The Alternative Pathway and the Thioester Amplification Loop (C3bBb)

Native C3 (like C4) harbors a buried intramolecular thioester bond (–Cys–S–C(=O)–CH₂–CH₂–Gln–) within its thioester-containing domain (TED). In blood plasma, this strained bond undergoes slow, spontaneous nucleophilic hydrolysis by water at a basal rate of ~0.5% to 1% per hour—a process termed "tick-over"—generating a conformationally altered fluid-phase molecule, C3(H₂O). C3(H₂O) binds plasma Factor B in the presence of Mg²⁺, allowing the constitutively active plasma protease Factor D (adipsin) to cleave Factor B into Ba and Bb, yielding a short-lived fluid-phase C3 convertase, C3(H₂O)Bb.

This fluid-phase convertase continuously generates small quantities of nascent C3b, in which the internal thioester bond is abruptly exposed to the solvent. If nascent C3b does not encounter a nucleophile within ~60 microseconds (a diffusion radius of <40 nm), its thioester reacts harmlessly with bulk water (H₂O) and is inactivated. However, if C3b is generated immediately adjacent to a bacterial, fungal, or viral membrane, its thioester reacts covalently with surface hydroxyl or amine groups. Surface-bound C3b then binds Factor B, which is cleaved by Factor D to form the membrane-bound alternative C3 convertase (C3bBb). Binding of the oligomeric plasma protein properdin (Factor P) stabilizes the C3bBb complex 10-fold (extending its half-life t_1/2 from ~90 s to ~15–30 min). Because every C3b deposited by any of the three pathways can bind Factor B to form new C3bBb complexes, the alternative pathway functions as an autocatalytic positive-feedback amplification loop (with surface density growing as N(t) = N₀ e^kt prior to steric saturation) that deposits over 2 × 10⁶ molecules of C3b onto a single bacterium within 5 minutes.

---

1. Opsonization and Phagocytic Clearance (C3b / iC3b): Covalent coating of a microbe with C3b and its proteolytically clipped derivative iC3b acts as a molecular tag (opsonin) recognized by Complement Receptors CR1 (CD35), CR3 (CD11b/CD18, Mac-1), and CR4 (CD11c/CD18) on neutrophils, monocytes, and macrophages, stimulating phagocytosis by >100-fold. Furthermore, erythrocytes carry ~500–1,000 copies of CR1 per cell, binding C3b-coated soluble antigen–antibody immune complexes in the bloodstream and ferrying them to hepatic Kupffer cells and splenic macrophages for disposal.
2. Anaphylatoxin-Mediated Inflammation (C5a > C3a > C4a): The small cationic cleavage peptides C5a (~11 kDa, the most potent, active at nanomolar concentrations) and C3a (~9 kDa) bind seven-transmembrane G-protein-coupled receptors (C5aR1 [CD88] and C3aR) on mast cells, basophils, vascular endothelium, and myeloid leukocytes. They trigger mast-cell degranulation and histamine release, smooth muscle contraction, increased vascular permeability, upregulation of endothelial P-selectin and ICAM-1, and directed chemotaxis of neutrophils to the site of inflammation.
3. The Terminal Lytic Pathway and Membrane Attack Complex (MAC, C5b–9): Attachment of an additional C3b subunit to a C3 convertase shifts its substrate specificity from C3 to C5, forming the C5 convertase (C4b2a3b in the classical/lectin pathways; C3bBbC3b in the alternative pathway). C5 convertase cleaves C5 into soluble C5a and C5b. Without further proteolysis, nascent C5b sequentially binds C6 and C7, inducing a hydrophilic-to-amphiphilic conformational transition that inserts the C5b67 complex into the outer leaflet of the target lipid bilayer. Binding of C8 (C8αβγ) penetrates the hydrophobic membrane core and nucleates the polymerization of 12 to 18 molecules of C9 into a hollow, giant transmembrane β-barrel cylinder (C5b678(C9)_12–18, outer diameter ~200 Å, inner pore diameter ~100 Å). This open pore dissipates transmembrane ion gradients and drives osmotic water influx and colloid-osmotic lysis. Because Gram-positive bacteria possess a thick (~20–80 nm) peptidoglycan cell wall that prevents C5b67 from reaching the cytoplasmic membrane, MAC lysis is uniquely critical against thin-walled Gram-negative bacteria—specifically Neisseria meningitidis and Neisseria gonorrhoeae; human genetic deficiencies in terminal components (C5, C6, C7, C8, or C9) or properdin confer a >1,000-fold increased susceptibility exclusively to recurrent disseminated Neisseria infections.

---

Because nascent C3b and C5b67 can deposit indiscriminately on adjacent healthy host cells, mammalian cells express a battery of fluid-phase and membrane-bound complement regulators to restrict activation exclusively to foreign surfaces:

• C1-Inhibitor (C1-INH, SERPING1): A plasma serpin (serine protease inhibitor) that covalently traps active C1r, C1s, MASP-1, MASP-2, and plasma kallikrein. Heterozygous deficiency of C1-INH causes hereditary angioedema (HAE), characterized by episodic subcutaneous and laryngeal swelling driven primarily by unchecked kallikrein cleavage of high-molecular-weight kininogen into the vasodilator peptide bradykinin.
• Factor H and Factor I: Soluble plasma Factor H possesses polyanion-binding domains that specifically recognize sialic acid and glycosaminoglycans (heparin/heparan sulfate) present on vertebrate host membranes but absent on most microbes. On host cells, Factor H accelerates the dissociation of Bb from C3bBb (decay-accelerating activity) and serves as a cofactor for the serine protease Factor I, which permanently cleaves C3b into inactive iC3b (which can still opsonize but cannot form a C3 convertase). Loss-of-function mutations in Factor H cause atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD, Y402H polymorphism).
• CD55 (Decay-Accelerating Factor, DAF) and CD59 (Protectin): Attached to host cell plasma membranes via a glycosylphosphatidylinositol (GPI) glycolipid anchor, CD55 dissociates C4b2a and C3bBb convertases, while CD59 binds C5b–8 to block the polymerization of C9 into the Membrane Attack Complex. Somatic mutation of the X-linked PIGA gene in a hematopoietic stem cell abolishes GPI-anchor synthesis, leaving progeny erythrocytes devoid of both CD55 and CD59 and causing paroxysmal nocturnal hemoglobinuria (PNH)—chronic intravascular complement-mediated hemolysis and thrombosis, which is treated clinically with the humanized anti-C5 monoclonal antibody eculizumab or the anti-Factor B inhibitor iptacopan.

---

How does the alternative complement pathway distinguish between foreign bacteria and healthy host cells?

The alternative pathway continuously deposits small amounts of covalent C3b onto all nearby surfaces via spontaneous "tick-over" hydrolysis. Healthy vertebrate host cells are coated with terminal sialic acid residues and express GPI-anchored regulators (CD55/DAF and CD46/MCP); sialic acid recruits plasma Factor H, which dissociates C3bBb and enables Factor I to cleave C3b into inactive iC3b. Bacterial and fungal cell walls lack host sialic acids and regulators, allowing C3bBb to amplify unchecked.

Why do patients lacking terminal complement proteins (C5–C9) suffer specifically from Neisseria infections?

When a person has a genetic deficiency in C5, C6, C7, C8, or C9, they cannot assemble the pore-forming Membrane Attack Complex (MAC), yet their early complement pathways (C1–C3) remain fully intact and can still opsonize most bacteria with C3b for phagocytic destruction. Most Gram-positive and enteric bacteria are efficiently killed by C3b-mediated phagocytosis, whereas encapsulated Gram-negative Neisseria meningitidis and Neisseria gonorrhoeae resist phagocytic killing and require direct osmotic lysis by the MAC across their outer membrane.

What causes red blood cell lysis in paroxysmal nocturnal hemoglobinuria (PNH)?

Paroxysmal nocturnal hemoglobinuria results from an acquired somatic mutation in the X-linked PIGA gene within a bone marrow hematopoietic stem cell. PIGA is required to synthesize glycosylphosphatidylinositol (GPI) lipid anchors that tether the complement-regulatory proteins CD55 (decay-accelerating factor) and CD59 (protectin) to the cell surface. Without CD55 to dismantle C3 convertases and CD59 to block C9 pore insertion, PNH red blood cells are continuously lysed by basal alternative-pathway complement activation.

---

1. Walport, M. J. (2001). "Complement. First of two parts." The New England Journal of Medicine, 344(14), 1058–1066. https://doi.org/10.1056/NEJM200104053441406
2. Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010). "Complement: a key system for immune surveillance and homeostasis." Nature Immunology, 11(9), 785–797. https://doi.org/10.1038/ni.1923
3. Janssen, B. J. C., Christodoulidou, A., McCarthy, A., Lambris, J. D., & Gros, P. (2006). "Structure of C3b reveals conformational changes that underlie complement activity." Nature, 444(7116), 213–216. https://doi.org/10.1038/nature05172
4. Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015). "Complement system part I – molecular mechanisms of activation and regulation." Frontiers in Immunology, 6, 262. https://doi.org/10.3389/fimmu.2015.00262